{"nctId":"NCT02329834","briefTitle":"Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure","startDateStruct":{"date":"2015-04"},"conditions":["Heart Failure"],"count":23,"armGroups":[{"label":"Treatment Sequence 1","type":"EXPERIMENTAL","interventionNames":["Drug: Fursemide Injection Solution for subcutaneous administration (80 mg)","Drug: Furosemide Injection, USP"]},{"label":"Treatment Sequence 2","type":"EXPERIMENTAL","interventionNames":["Drug: Fursemide Injection Solution for subcutaneous administration (80 mg)","Drug: Furosemide Injection, USP"]}],"interventions":[{"name":"Fursemide Injection Solution for subcutaneous administration (80 mg)","otherNames":[]},{"name":"Furosemide Injection, USP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities.\n* Male and female subjects ≥18 years of age, with body volume and weight \\<130 kg and body mass index (BMI) \\<38 kg/m2\n* Females will be non-pregnant, non-lactating, and post-menopausal, surgically sterile (e.g., tubal ligation, hysterectomy), or use TWO (2) of the following forms of contraception: IUD, IUD with spermicide, female condom with spermicide, contraceptive sponge with spermicide, an intravaginal system, diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who agrees to use a male condom with spermicide, a sterile sexual partner, OR abstinence\n* History of at least 3 months treated heart failure (NYHA class II/III) with presence of symptoms of chronic volume overload requiring ongoing treatment with oral furosemide at a dose of ≥ 40 mg per day for at least 30 days prior to baseline\n* NT-proBNP \\> 300 pg/mL or BNP \\> 100 pg/mL\n* Agrees to abstain from using alcohol, caffeine-containing products, and tobacco-/nicotine-containing products through CRU discharge (period 2).\n* Able to participate in the study in the opinion of the investigator\n* Has the ability to understand the requirements of the study and is willing to comply with all study procedures\n\nExclusion Criteria:\n\n* Acute Decompensated Heart Failure (ADHF) or recent history of hospitalization for heart failure in the last 4 weeks\n* Worsening of signs or symptoms of heart failure in the two weeks prior to the Screening, or those expected to require intravenous loop diuretics or in-patient treatment for heart failure during the study\n* Systolic BP (SBP) \\< 90 mm Hg\n* Temperature \\> 38°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment\n* Serum sodium \\< 130 mEq/L and Serum potassium \\< 3.0 mEq/L\n* Significant other cardiac abnormalities which may interfere with study participation or study assessments\n* Current or planned treatment during the study with any IV therapies, including inotropic agents, vasopressors, levosimendan, nesiritide or analogues; or mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)\n* Diagnosed with Type I diabetes mellitus or Type II diabetes requiring insulin therapy\n* Presence or need for urinary catheterization, urinary tract abnormality, or disorder interfering with urination\n* Impaired renal function, defined as an estimated glomerular filtration rate (eGFR) on admission \\< 45 mL/min/1.73m2, calculated using the simplified Modification of Diet in Renal Disease (sMDRD) equation\n* Indication of moderate-to-severe hepatic dysfunctions as determined by the investigator\n* Administration of intravenous radiographic contrast agent within 72 hours prior to Screening or acute contrast-induced nephropathy at the time of Screening\n* Major surgery within 30 days prior to Screening\n* Administration of an investigational drug or implantation of investigational device, or participation in another interventional trial, within 30 days prior to Screening\n* Any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study\n* Positive test for hepatitis B, hepatitis C, or HIV at Screening\n* Positive urine drug screen at Screening or Baseline\n* Concomitant use of any drugs known to interact with furosemide\n* History of alcohol abuse within 6 months prior to screening, as determined by the Investigator\n* Positive alcohol breath test on admission to the CRU\n* History of severe allergic or hypersensitivity reactions to furosemide\n* Donation of greater than 100 mL of either whole blood or plasma within 30 days prior to study drug administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cmax","description":"Maximum observed plasma concentration of Furosemide","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8580","spread":"2540"},{"groupId":"OG001","value":"2040","spread":"449"}]}]}]},{"type":"PRIMARY","title":"Tmax","description":"Time to achieve maximum observed Furosemide plasma concentration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"AUClast","description":"The area under the plasma concentration versus time curve from time 0 (pre-dose) to the last quantifiable time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13000","spread":"4050"},{"groupId":"OG001","value":"13000","spread":"4000"}]}]}]},{"type":"PRIMARY","title":"AUCinf","description":"The area under the plasma concentration-time curve from time 0 (pre-dose) to time of last measurable plasma concentration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13200","spread":"4170"},{"groupId":"OG001","value":"13100","spread":"4010"}]}]}]},{"type":"PRIMARY","title":"AUCext","description":"The percentage of AUC that is extrapolated beyond the last measurable concentration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.912","spread":"0.631"},{"groupId":"OG001","value":"1.05","spread":"1.29"}]}]}]},{"type":"PRIMARY","title":"λz","description":"Apparent plasma terminal-phase elimination rate constant","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.277","spread":"0.0365"},{"groupId":"OG001","value":"0.238","spread":"0.0732"}]}]}]},{"type":"PRIMARY","title":"t 1/2","description":"Terminal-phase half life","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.55","spread":"0.339"},{"groupId":"OG001","value":"3.16","spread":"0.911"}]}]}]},{"type":"PRIMARY","title":"Volume of Distribution, Terminal Phase","description":"Systemic Volume of distribution, terminal phase for IV furosemide and Apparent Volume of distribution, terminal phase for SC furosemide","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":"9.15"},{"groupId":"OG001","value":"28.5","spread":"5.28"}]}]}]},{"type":"PRIMARY","title":"CL","description":"Systemic Clearance for IV furosemide and Apparent Systemic Clearance for SC furosemide","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.71","spread":"2.31"},{"groupId":"OG001","value":"6.71","spread":"2.21"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Application site erythema","Application site edema","Nodule","BNP elevated","Peripheral pulse decreased"]}}}